Dextran-Guanidine-Biphosphonate Conjugates for Bone Metastasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bone metastasis, particularly in advanced breast and prostate cancer, often result in uncontrolled skeletal pain and are not sufficiently effective, with many patients experiencing persistent pain despite standard therapies, highlighting a need for more effective medications targeting bone tumors and osteoporosis.
Innovation Solution
A modified hydroxypolymer conjugate, specifically a dextran-guanidine-biphosphonate compound, is developed, where biphosphonate and guanidine compounds are covalently coupled to activated hydroxyl groups of dextran, providing both bone-seeking and tumor-killing properties, including anti-osteoclastic activity, for the treatment of metastatic bone lesions and osteoporosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard treatments (analgesics and chemotherapeutic drugs) are used for bone metastasis, then some pain palliation is achieved, but many patients continue with uncontrolled severe pain
Solution Approach 1:
The treatment approach is segmented into two distinct functional components: biphosphonate groups that target bone metastasis sites specifically, and guanidine groups that provide tumor cell killing activity. This segmentation allows each component to perform its specialized function, with the biphosphonate directing the conjugate to bone lesions and the guanidine executing the therapeutic effect, thereby achieving more reliable pain palliation than non-segmented standard treatments.
Solution Approach 2:
The invention employs a composite structure by covalently coupling biphosphonate and guanidine compounds to a dextran polymer backbone. This composite material combines the bone-targeting capability of biphosphonates with the tumor-killing activity of guanidine compounds, creating a multifunctional agent that simultaneously addresses both localization and therapeutic efficacy, resolving the contradiction between achieving pain relief and avoiding uncontrolled pain.
2Reliability
If conventional anticancer drugs are used, then tumor cell killing is achieved, but toxic effects and unfavorable side-effect profiles occur
Solution Approach 1:
The conjugate exhibits local quality by concentrating tumor cell killing activity specifically at bone metastasis sites through the bone-seeking biphosphonate groups. The guanidine moieties exert their cytotoxic effect locally where the conjugate accumulates in bone lesions, rather than systemically throughout the body. This localized action maintains high tumor cell killing efficacy at the target site while minimizing toxic effects and side-effects on healthy tissues, resolving the contradiction between efficacy and safety.
3Object-generated harmful factors
If dextran is used as a hydroxypolymer base, then high tolerability and non-toxic properties are achieved, but limited therapeutic activity against bone tumors is present
Solution Approach 1:
The invention merges the favorable safety profile of dextran with the therapeutic activities of biphosphonate and guanidine compounds. The dextran polymer serves as a non-toxic carrier that provides high tolerability, while the attached biphosphonate groups confer bone-targeting capability and the guanidine groups provide tumor cell killing activity. This merging transforms the initially inactive or minimally active dextran into a highly effective bone tumor therapeutic with both safety and efficacy, resolving the contradiction between non-toxicity and antitumor activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dextran-guanidine-biphosphonate conjugate demonstrates enhanced tumor cell killing efficacy compared to established anticancer drugs and shows potential for effective pain palliation and treatment of bone metastasis, as well as imaging and identification of tumor lesions, with favorable handling and side-effect profiles for medical staff and patients.
Implementation Method 1
biphosphonate and guanidine compounds having at least one free amino group are covalently coupled to the activated hydroxyl groups of a hydroxypolymer
Implementation Method 2
biphosphonate and guanidine compounds having at least one free amino group are covalently coupled to the activated hydroxyl groups of a hydroxypolymer
Implementation Method 3
modified hydroxypolymer conjugates substituted with bone seeking and tumor killing moieties
Implementation Method 4
The modified hydroxypolymer conjugate is useful as a medicine for treating bone cancer, osteoporosis, etc. The hydroxypolymer dextran conjugate is used for treating metastatic bone lesions in refractory prostate cancer
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present inven tion is related to a modified hydroxypolymer conjugate, preferably a dextran-guanidine-biphosphonate conjugate for treating not only skeletal tumors i.e. bone metastasis, particularly bone metastasis related to hormone refractory prostate cancer HRPC and breast cancer, but also osteoporosis. A method for producing and using said hydroxypolymer conjugate is also disclosed.